Skip to content

HUTCHMED (China) Ltd

HCM Nasdaq SEC CIK 1648257

Follow HUTCHMED (China) Weekly email: filings, results, news

News

9 stories filed under HUTCHMED (China), grouped into ongoing threads

HCM discusses

Thread · 3 stories

HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 - Slideshow

Markets 17 d ago also on GSK

HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript

Markets 21 d ago also on GSK

Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript

Markets 27 d ago also on CYTK III

More coverage

AIM movers: Hutchmed licence deal with GSK and Futura Medical assessing potential sale

Markets 21 d ago also on GSK

Dayforce Named a Leader in the 2026 Gartner® Magic Quadrant™ for HCM Suites for 1,000+ Employee Enterprises for Seventh Consecutive Year

Markets 22 d ago also on IT

Truist reiterates Buy on Cytokinetics stock, $112 target on HCM potential

Markets 23 d ago also on CYTK

HUTCHMED Secures NMPA Conditional Approval for ATLED® (Fanregratinib) to Treat FGFR2-Altered Intrahepatic Cholangiocarcinoma in China

Markets 27 d ago

HUTCHMED (HCM) Reports Insolvency Proceedings at Former Director Dr Dan Eldar’s Ex-Company S.D. Sight Diagnostics

Policy 37 d ago

UK Healthcare Stocks Split Between Service Patient activity and Clinical Milestones

Policy 42 d ago

Profile

Headquarters: HONG KONG
Sector: Healthcare
Industry: Pharmaceutical Preparations

Peers

Where this page comes from

Profile · SEC EDGAR

News · 9 stories clustered from the RSS aggregator